Abeona Therapeutics (NASDAQ: ABEO) is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona’s lead programs include ABO-102 and ABO-101, adeno-associated virus based gene therapies for Sanfilippo syndrome. Abeona is also developing EB-101 for recessive dystrophic epidermolysis bullosa, EB-201 for epidermolysis bullosa, ABO-201 gene therapy for juvenile Batten disease, ABO-202 gene therapy for treatment of infantile Batten disease, and ABO-301 for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha™ for inherited COPD, using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit the company’s website at www.abeonatherapeutics.com.
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
